Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Frank G. Basile"'
Autor:
Scott Daigle, David Ciccone, Samantha Carreiro, Christine Loh, Neelu Kaila, Fu-Shan Kuo, Scott Boiko, Gene Yau, Esha A Gangolli, Denise Levasseur, Bhaskar Srivastava, Frank G Basile
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d7116d7f7b804a0885f65ce7d1bf0e25
Autor:
Scott Daigle, Sunil Sharma, Xinyan Zhang, Martin Gutierrez, Patricia Fraser, David Sommerhalder, Scott Boiko, Esha A Gangolli, Bhaskar Srivastava, Frank G Basile, Marcus Noel, Amanda Hoerres, Nawaid Rana, Rama Balaraman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eeeb277cba37407485a3b247289a090b
Autor:
Btissam Chami, Makoto Okuda, Morvarid Moayeri, France Pirenne, Yoko Hidaka, Ashok Nambiar, Zhili Song, Olivier Bedel, Bailin Zhang, Joern Hopke, Gejing Deng, Chen Zhu, Sandrine Macé, Marielle Chiron, Francisco Adrian, Taro Fukao, Frank G. Basile, Thomas Martin
Publikováno v:
Transfusion. 62:2334-2348
There are two FDA-approved anti-CD38 monoclonal antibodies for treatment of multiple myeloma: isatuximab and daratumumab. Owing to expression of CD38 on reagent red blood cells (RBCs), these antibodies interfere with indirect antiglobulin tests (IATs
Autor:
Edie Weller, Kaitlen Reyes, James J. Vredenburgh, Adam Boruchov, Kimberly Noonan, Paul G. Richardson, Rachid Baz, Jacob P. Laubach, Abdel Kareem Azab, Houry Leblebjian, Robert L. Schlossman, Irene M. Ghobrial, Frank G. Basile, Pamela A. Crilley, Kenneth C. Anderson, Patrick Henrick, Michael Constantine, Stacey Chuma, Nikhil C. Munshi, Kenneth H. Shain, Kalvis Hornburg, Claudia E. Paba-Prada, Philippe Armand, Diane Warren, Yuji Mishima, Lorenzo Trippa, Chia Jen Liu, Oksana Zavidij
Publikováno v:
American Journal of Hematology. 94:1244-1253
We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with
Autor:
Adam Sharp, Anja Williams, Sarah Patricia Blagden, Elizabeth Ruth Plummer, Daniel Hochhauser, Matthew Krebs, Simon Pacey, T.R. Jeffry Evans, Sarah Whelan, Srinand Nandakumar, Seema Rogers, Katherine L. Jameson, Frank G. Basile, Johann S. De Bono, Hendrik-Tobias Arkenau
Publikováno v:
Journal of Clinical Oncology. 40:TPS2691-TPS2691
TPS2691 Background: Casitas B-lineage lymphoma proto-oncogene B (CBL-B) is an E3 ubiquitin ligase expressed in multiple immune cell lineages, which in contrast to cell surface immune checkpoints, acts as a regulator of both T and NK cell activation.
Autor:
Eugenia Girda, Emese Zsiros, John Nakayama, Sarah Whelan, Srinand Nandakumar, Seema Rogers, Beverly Benson, Frank G. Basile, Michael T. Lotze, Robert James Brown, Robert Michael Wenham
Publikováno v:
Journal of Clinical Oncology. 40:TPS5602-TPS5602
TPS5602 Background: Tumor-infiltrating lymphocytes (TIL) are a heterogeneous population of T cells that recognize multiple endogenous tumor antigens but may have developed an exhausted phenotype due to the tumor microenvironment. While existing TIL t
Autor:
Marvin Cohen, Feng Yin, Frank G. Basile, Bin Fan, Caroline Almon, Michelle Mobilia, David Dai, Hua Yang, Raj Nagaraja, Huansheng Xu
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(1)
Ivosidenib, a small-molecule inhibitor of mutant isocitrate dehydrogenase 1, is primarily cleared by hepatic metabolism. This open-label study investigated the impact of hepatic impairment on ivosidenib pharmacokinetics (ClinicalTrials.gov: NCT032825
Autor:
Lorenzo Trippa, Jacob P. Laubach, Paul G. Richardson, Elizabeth O'Donnell, Kathleen J. Lively, Robert L. Schlossman, Tianqi Chen, Irene M. Ghobrial, Andrew Yee, Philip M. Wade, Carol Ann Huff, Frank G. Basile, Nikhil C. Munshi, Jill N. Burke, Claudia E. Paba-Prada, Kenneth C. Anderson, Hannah Lyons, Cynthia C. Harrington, Noopur Raje
Publikováno v:
British Journal of Haematology. 182:222-230
We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population a
Autor:
Monique C. Minnema, Ellie Im, Frank G. Basile, Brandon E. Kremer, L. Mary Smith, Paul G. Richardson, Katarina Uttervall, Kevin W. Song, Paula Rodriguez-Otero, Hang Quach, Ajay K. Nooka, Ira Gupta, Herbert Struemper, Christoph M. Ahlers, Anne Yeakey, Morrys Kaisermann, Beata Holkova, Nicola Jackson, Suzanne Trudel, Natalie S. Callander, Rocio Montes de Oca
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S156
Background Single-agent belamaf, a B-cell maturation antigen-targeting antibody-drug conjugate, induced durable responses with a manageable safety profile in patients with RRMM at 13 months of follow-up (DREAMM-2; NCT03525678). The unique multimodal
Autor:
Kevin Marks, Patricia Martin-Romano, Geoffrey I. Shapiro, Howard A. Burris, Rebecca S. Heist, Sophie Postel-Vinay, Keith T. Flaherty, Michael Cooper, Elena Garralda, Frederick Wilson, Khanh T. Do, Yanwei Zhang, Elia Aguado-Fraile, Varsha Iyer, Caroline Almon, Frank G. Basile, Salah Nabhan, Gerburg M. Wulf, Mrinal M. Gounder
Publikováno v:
Molecular Cancer Therapeutics. 18:PR03-PR03
Background: Homozygous deletion of MTAP, the gene encoding the metabolic enzyme methylthioadenosine phosphorylase, occurs in ~15% of human malignancies. Tumor cells with this deletion are selectively vulnerable to decreases in the methyl donor S-aden